KB 104
Alternative Names: KB-104Latest Information Update: 05 Mar 2024
At a glance
- Originator Krystal Biotech
- Class Gene therapies; Skin disorder therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Netherton Syndrome
Most Recent Events
- 29 Feb 2024 Krystal Biotech has patent protection for the composition of replication defective HSV vectors encoding SPINK5 in USA before February 2024
- 29 Feb 2024 KB 104 is still in preclinical trials for Netherton syndrome in USA (Topial)
- 07 Nov 2022 Krystal Biotech intends to submit an IND application for Congenital ichthyosiform erythroderma (Netherton's syndrome) in first half of 2023